Comparison of Analytical Values D-Dimer, Glucose, Ferritin and C-Reactive Protein of Symptomatic and Asymptomatic COVID-19 Patients증상 및 무증상 COVID-19 환자의 D-이량체, 포도당, 페리틴 및 C-반응성 단백질의 분석 값 비교Article Published on 2022-04-282022-09-11 Journal: International Journal of Environmental Research an [Category] COVID19(2023년), SARS, 바이오마커, [키워드] age alteration analysed Asymptomatic asymptomatic patients Biomarkers C-reactive protein C-reactive protein) carried chain Chain Reaction Complication correlated COVID-19 cross-sectional cross-sectional study D-dimer develop evaluate ferritins Frequency Glucose glucose. hospitalisation hospitalised involved Laboratory less mild symptoms occurred parameter parameters participant pathology Patient patients polymerase chain reaction positive predict predictor reaction reduce risk Serum ferritin severe symptom severe symptoms severity Spain statistically significant statistically significant difference symptomatic symptomatic patient test result the patient value [DOI] 10.3390/ijerph19095354 PMC 바로가기 [Article Type] Article
Multivariate profile and acute-phase correlates of cognitive deficits in a COVID-19 hospitalised cohortResearch article Published on 2022-04-282022-10-05 Journal: EClinicalMedicine [Category] 바이오마커, [키워드] Academy Accuracy acute illness acute phase age Anxiety association Attention calculated Cambridge characteristic clinical feature Clinical research Cognition cognitive Cognitive assessment cognitive deficit Cognitive function Cohort condition controls COVID-19 Critical care datasets Dementia demographic factor Department Depression determine deviation Effect expected expressed facility finding foundation funding highlighting hospital Hospital admission hospitalised Imperial College London individual less magnitude mechanically ventilated Medical Research Council memory mental health multivariate NHS NIHR Planning Post-traumatic stress disorder predicted preliminary evidence profile Reasoning reduced required Research response scientist severe COVID-19 severity significantly Standard deviation statistical significance supported survivor technology Trust Wellcome Trust with COVID-19 [DOI] 10.1016/j.eclinm.2022.101417 [Article Type] Research article
Distinct clinical symptom patterns in patients hospitalised with COVID-19 in an analysis of 59,011 patients in the ISARIC-4C study Research Published on 2022-04-272022-10-05 Journal: Scientific Reports [Category] 유전자 메커니즘, 진단, 치료법, [키워드] 30-Day mortality affecting Analysis applied approach association clinical Clinical data clinical symptom clinically Clustering Community Confusion cough COVID-19 determine diagnostic diarrhoea disease duration of symptom Dyspnoea fatigue female Fever Gastrointestinal symptom granular hospitalised hospitalised patient identify in-hospital mortality Interpretation ISARIC Mild Mortality no symptoms observation Older organ system Patient pauci-symptomatic presentation presenting prospective cohort recruited recruitment Replication replication analysis reported robust self-reported symptom Symptom Symptoms therapeutic Unsupervised clustering utility vomiting with COVID-19 [DOI] 10.1038/s41598-022-08032-3 [Article Type] Research
Influence of socioeconomic status on functional recovery after ARDS caused by SARS-CoV-2: a multicentre, observational studyObservational Study Published on 2022-04-222022-10-05 Journal: BMJ Open [Category] COVID19(2023년), SARS, 임상, [키워드] acute respiratory distress alteration approved ARDS Berlin criteria Care caused Chest CT chest CT scan cohort study Compliance COVID-19 Critical Critical care defined Desaturation develop diagnosed discharge disease eligible Ethics facilitator finding Follow-up form functional Health healthcare High-flow nasal oxygen hospitalised ICU identify impair include Inclusion independent individual influence informed consent form initial Intensive intensive & intensive care International lung multicentre National outcomes oxygen Patient patients with COVID-19 peer-reviewed performed Primary outcome Prognosis protection protocol Pulmonary function tests Quality of life rehabilitation respiratory Respiratory function respiratory infections Respiratory Support risk SARS-COV-2 infection Severe case severity Study protocol syndrome [DOI] 10.1136/bmjopen-2021-057368 PMC 바로가기 [Article Type] Observational Study
Comparison of UK paediatric SARS-CoV-2 admissions across the first and second pandemic waves Research Published on 2022-04-222022-10-05 Journal: Pediatric Research [Category] COVID19(2023년), SARS, 치료제, [키워드] Admission Alpha antibiotic use B.1.1.7 changes in Characteristics children clinical Clinical characteristics co-morbidity Cohort Comorbidity Critical care died disease severity Evidence First wave had no hospitalised hospitals hypothesised Impact less main analysis MIS-C multicentre no evidence of Observational cohort study pandemic Patient proportion Prospective reported Respiratory Support Result SAGE SARS-CoV-2 SARS-COV-2 infection score second wave severity of COVID-19 shielding Support symptomatic those with MIS-C Treatment vaccination variant were excluded [DOI] 10.1038/s41390-022-02052-5 [Article Type] Research
Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA)Research article Published on 2022-04-212022-10-05 Journal: EClinicalMedicine [Category] 바이오마커, 임상, [키워드] 28-day mortality 95% CI anti-SARS-CoV-2 antibody antibody Antibody Response assessment assigned authority benefit clearance combination therapy Coronavirus disease 2019 Coronavirus disease-19 COVACTA COVID-19 Department development died discharged double-blind Effect Efficacy and safety Europe finding funding Future Hoffmann-La Roche hospital hospital discharge hospitalised Host immune response Human impair IMPROVE Infection intensive care interleukin-6 intravenous tocilizumab investigated Mortality Nasopharyngeal swab neutralising North America occurred office other treatments Patient patient selection patients with COVID-19 Placebo placebo-controlled trial polymerase chain positive test result Potential biomarker randomised randomised controlled trial Randomly respiratory response SARS-CoV-2 SARS-CoV-2 viral load Secretary serum serum samples severe acute respiratory syndrome coronavirus-2 tested Tocilizumab Treatment viral clearance Viral load with COVID-19 [DOI] 10.1016/j.eclinm.2022.101409 [Article Type] Research article
An open label randomized clinical trial of Indomethacin for mild and moderate hospitalised Covid-19 patients경증 및 중등도 입원 코비드-19 환자를 위한 인도메타신의 공개 라벨 무작위 임상 시험Randomized Controlled Trial Published on 2022-04-192022-09-12 Journal: Scientific Reports [Category] COVID19(2023년), SARS, 신약개발, 임상, 진단, 치료법, 치료제, [키워드] addition adjuvant therapies Admission adverse event afebrile anti-inflammatory drug Antiviral Arm ARMS Block randomisation blood chemistry clinical trial control arm coronavirus disease cough COVID-19 COVID-19 patient Desaturation discharge effective Efficacy and safety evaluated Fever Follow-up High-flow oxygen hospital hospitalised indomethacin Ivermectin medication Mild moderate myalgia open label Paracetamol parameters Patient patients primary endpoint profile provided randomised randomized clinical trial reported required retained Safe Secondary endpoints Standard of care Symptom symptomatic tiredness [DOI] 10.1038/s41598-022-10370-1 PMC 바로가기 [Article Type] Randomized Controlled Trial
Mortality rates among COVID-19 patients hospitalised during the first three waves of the epidemic in Milan, Italy: A prospective observational studyObservational Study Published on 2022-04-112022-10-04 Journal: PLoS ONE [Category] 임상, [키워드] 95% CI 95% confidence interval adjusted Admission age association changed Comorbidity confounders COVID-19 COVID-19 patient Cox model Critical disease death disease severity First wave hazard ratio hospital hospitalisation hospitalised hospitalised COVID-19 patient Italy Mortality mortality rate no difference no significant difference obesity Patient presenting Probability prospective cohort study prospective observational study reduced risk risk risk of death second wave Sex significantly lower study period survival symptom onset the epidemic the Kaplan-Meier method the patient were used [DOI] 10.1371/journal.pone.0263548 PMC 바로가기 [Article Type] Observational Study
Viral Evolution and Immunology of SARS-CoV-2 in a Persistent Infection after Treatment with Rituximab리툭시맙 치료 후 지속적인 감염에서 SARS-CoV-2의 바이러스 진화 및 면역학Case Reports Published on 2022-04-032022-09-11 Journal: Viruses [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] accelerated accumulated accumulation Asymptomatic clade Clinical course clinical implications Community Complete Complete Remission Ct-value Culture Deletion deletions demonstrated described facilitate growth hospitalised Immunocompromised Immunocompromised host immunocompromised individual immunocompromised individuals Immunocompromised patient Immunocompromised patients immunologic response immunosuppressive immunosuppressive therapy increase in individuals Infection prevention lymphocyte Lymphocyte count lymphoma measure Mutation N-terminal domain Nasopharyngeal swab Patient persistence persistent persistent infection positive Prolonged qPCR remained rituximab RT-qPCR SARS-CoV-2 SARS-CoV-2 genome Spike protein Spread the SARS-CoV-2 genome therapy variants variants of concern variants of concern (VOC) Viral viral evolution virus VoC WGS whole genome Whole genome sequencing wildtype [DOI] 10.3390/v14040752 PMC 바로가기 [Article Type] Case Reports
Natriuretic peptide level at heart failure diagnosis and risk of hospitalisation and death in England 2004-20182004-2018년 영국에서 심부전 진단 시 나트륨 이뇨 펩티드 수준 및 입원 및 사망 위험Article Published on 2022-04-012022-09-11 Journal: Heart (British Cardiac Society) [Category] COVID19(2023년), MERS, SARS, 바이오마커, [키워드] 95% CI age all-cause mortality rates association baseline clinical cohort study competing COVID-19 death diagnosed Diagnosis diagnostic England greater guideline Healthcare system Healthcare systems heart heart failure hospitalisation hospitalised IMPROVE IQR mandatory median time men moderate Mortality mortality rate mortality rates Natriuretic NT-proBNP participant Patient peptide Practice pressure Prevent primary care Referral Research risk secondary care survival Treatment while [DOI] 10.1136/heartjnl-2021-319196 PMC 바로가기 [Article Type] Article